Skip to main content
SpringerLink
Log in
Book cover

Stem Cells and Cancer Stem Cells, Volume 1 pp 107–112Cite as

Is CD133 the Appropriate Stem Cell Marker for Glioma?

  • Chapter
  • First Online:

  • 1348 Accesses

Part of the book series: Stem Cells and Cancer Stem Cells ((STEM,volume 1))

Abstract

Stem cells have been accredited for their contribution towards tissue repair and regeneration, however, their potential to cause cancer is given more attention. CD133, a glioma stem cell marker has been linked to brain tumour proliferation and multi-drug resistance. Failure of CD133+ cells to define tumour relapse and an effective tumour forming ability of CD133– cells enhances the need to identify a selective and reliable stem cell marker. This review focuses on the undifferentiated and differentiated aspects of stem cells involving embryonic stem cell markers Oct4A and BMP2. In addition, alternative molecular targets have been enlisted that may help to further locate and eliminate tumour-initiating cells, thereby increasing the effectiveness of therapeutic drugs used to cure glioma.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • An JH, Lee SY, Jeon JY, Cho KG, Kim SU, Lee MA (2009) Identification of gliotropic factors that induce human stem cell migration to malignant tumor. J Proteome Res 8:2873–2881

    Article  PubMed  CAS  Google Scholar 

  • Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ, Andrews PW (2008) OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells 26:3068–3074

    Article  PubMed  CAS  Google Scholar 

  • Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760

    Article  PubMed  CAS  Google Scholar 

  • Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP (2007) CD133+ and CD133– glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010–4015

    Article  PubMed  CAS  Google Scholar 

  • Capper D, Gaiser T, Hartmann C, Habel A, Mueller W, Herold-Mende C, Von Deimling A, Siegelin MD (2009) Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down regulation of caspase-8 by promoter methylation. Acta Neuropathol 117:445–456

    Article  PubMed  CAS  Google Scholar 

  • Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM (2006) Cancer stem cells-perspective on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66:9339–9344

    Article  PubMed  CAS  Google Scholar 

  • Dittmar T, Nagler C, Schwitalla S, Reith G, Niggemann B, Zanker K (2009) Recurrence cancer stem cells – Made by cell fusion? Med Hypotheses 73:542–547

    Article  PubMed  CAS  Google Scholar 

  • Duelli D, Lazebnik Y (2003) Cell fusion: a hidden enemy? Cancer Cell 3:445–448

    Article  PubMed  CAS  Google Scholar 

  • Gidekel S, Pizov G, Bergman Y, Pikarsky E (2003) Oct-3/4 is a dose-dependent fate determinant. Cancer Cell 4:361–371

    Article  PubMed  CAS  Google Scholar 

  • Heck AJ, Mummery C, Whetton A, Oh S, Lee B, Pera M, Lemischka I, Krijgsveld J (2007) Proteome biology of stem cells. Stem Cell Res 1:7–8

    Article  PubMed  Google Scholar 

  • Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN (2009) The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8:3274–3284

    Article  PubMed  CAS  Google Scholar 

  • Heese O, Disko A, Zirkel D, Westphal M, Lamszus K (2005) Neural stem cell migration toward gliomas in vitro. Neuro Oncol 7:476–484

    Article  PubMed  CAS  Google Scholar 

  • Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP (2010) The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 70:719–729

    Article  PubMed  CAS  Google Scholar 

  • Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN (2009) Turning cancer cells inside-out: an exploration of glioma stem cell signalling pathways. J Biol Chem 284:16705–16709

    Article  PubMed  CAS  Google Scholar 

  • Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL (2009) Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol 94:1–19

    Article  PubMed  Google Scholar 

  • Liu HG, Zhang XH (2009) How to search for specific markers of cancer stem cells. Asian Pac J Cancer Prev 10:177–180

    PubMed  Google Scholar 

  • Lu W, Lee HK, Cazacu S, Finniss S, Xiang C, Zenklusen J, Fine HA, Rennert J, Berens ME, Mikkelsen T, Brodie C (2006) BMP2 is highly expressed in gliomas correlated with glioma patient survival and regulates the proliferation and migration of glioma cells. Proc Am Assoc Cancer Res 47:5266

    Google Scholar 

  • McCord AM, Jamal M, Shankavarum UT, Lang FF, Camphausen K, Tofilon PJ (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7:489–497

    Article  PubMed  CAS  Google Scholar 

  • Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME (2008) Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26:3015–3024

    Article  PubMed  CAS  Google Scholar 

  • Nakano I, Saigusa K, Kornblum HI (2008) BMPing off glioma stem cells. Cancer Cell 13:3–4

    Article  PubMed  CAS  Google Scholar 

  • Patel R, Shervington A (2009) Telomerase and DNA repair in glioma. Biochim Biophys Acta 1792:275–279

    PubMed  CAS  Google Scholar 

  • Piccrillo SGM, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444:761–765

    Article  Google Scholar 

  • Piccrillo SGM, Vescovi AL (2006) Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Scher Found Symp Proc 5:59–81

    Article  Google Scholar 

  • Pine SR, Ryan BM, Varticovski, L, Robles AI, Harris CC (2010) Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proc Natl Acad Sci USA 107:2195–2200

    Article  PubMed  CAS  Google Scholar 

  • Rajan P, Panchision DM, Newell LF, McKay RDG (2003) BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells. J Cell Biol 161:911–921

    Article  PubMed  CAS  Google Scholar 

  • Rajaraman R, Guernsey DL, Rajaraman MM, Rajaraman SR (2006) Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int 6:1–26

    Article  Google Scholar 

  • Schwartz PH, Bryant PJ, Fuja TJ, Su H, O’Dowd DK, Klassen H (2003) Isolation and characterization of neural progenitor cells from post-mortem human cortex. J Neurosci Res 74:838–851

    Article  PubMed  CAS  Google Scholar 

  • Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao JX (2008) Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One 3:e1652

    Article  PubMed  Google Scholar 

  • Shervington A, Lu C (2008) Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest 26:535–542

    Article  PubMed  CAS  Google Scholar 

  • Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828

    PubMed  CAS  Google Scholar 

  • Strojnik T, Rosland GV, Sakariassen PO, Kavalar R, Lah T (2007) Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 68:133–143

    Article  PubMed  Google Scholar 

  • Sun Y, Kong W, Falk A, Hu J, Zhou L, Pollard S, Smith A (2009) CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS One 4:e5498

    Article  PubMed  Google Scholar 

  • Virginie C, Dutoit V, Marino D, Deitrich P, Radovanoic I (2009) Limits of CD133 as a marker of glioma self-renewing cells. Int J Cancer 125:244–248

    Article  Google Scholar 

  • Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, Prestegarden L, Rosland G, Thorsen F, Stuhr L, Molven A, Bjerkvig R, Enger PO (2008) CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122:761–768

    Article  PubMed  CAS  Google Scholar 

  • Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14:123–129

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brain Tumour North West, Faculty of Science, University of Central Lancashire, Preston, UK

    Zarine Khan, Leroy Shervington & Amal Shervington

Authors
  1. Zarine Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leroy Shervington
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amal Shervington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amal Shervington .

Editor information

Editors and Affiliations

  1. , Kean University, Room 213, Library building, Morris Avenue 1000, Union, 07083, New Jersey, USA

    M.A. Hayat

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Khan, Z., Shervington, L., Shervington, A. (2012). Is CD133 the Appropriate Stem Cell Marker for Glioma?. In: Hayat, M. (eds) Stem Cells and Cancer Stem Cells, Volume 1. Stem Cells and Cancer Stem Cells, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-1709-1_13

Download citation

Publish with us

Policies and ethics

Search

Navigation